Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is a late-stage development biopharmaceutical company, primarily focused on researching and developing new cancer-fighting medicines. With a strong pipeline of novel anticancer agents that inhibit critical signaling pathways in cancer cells, there is strong potential for continued growth and success. Recent commercial results, positive data from clinical trials, and a strengthened balance sheet provide a strong foundation for continued success in the near and long term.

Bears say

Verastem is facing numerous risks, including challenges in R&D, regulatory approval, and commercial success, as well as increasing competition and potential for underwhelming product sales. While the company's current pipeline shows promise, the financial burden of further R&D and dilutive financing could be too much, and the upside potential of their KRAS G12D inhibitor VS-7375 may be limited in a crowded market. The recent change in fair value preferred warrant liability also raises concerns about the company's financial stability.

Verastem (VSTM) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.